Skip to main content
. 2016 Nov 16;7(52):86339–86349. doi: 10.18632/oncotarget.13404

Table 1. Clinico-pathological association of 18q deletion in all cancers, ERG-negative cancers and ERG-positive cancers.

All cancers ERG-negative cancers ERG-positive cancers
n 18q deletion (%) p value n 18q deletion (%) p value n 18q deletion (%) p value
All cancers 6881 7.5 3419 8.2 2977 6.4
Tumor stage
pT2 4360 6.4 < 0.0001 2260 6.9 0.0004 1751 5.1 < 0.0001
pT3a 1559 8.0 687 9.8 790 6.5
≥ pT3b 930 11.8 459 12.0 418 11.2
Gleason grade
≤ 3+3 1636 6.9 0.0013 799 7.9 0.1842 667 5.0 0.0011
3+4 3804 6.8 1826 7.5 1745 5.6
4+3 1058 10.1 569 10.2 428 10.3
≥ 4+4 344 9.9 208 9.6 116 10.3
PSA Level (ng/μl)
< 4 863 8.0 0.0630 377 7.4 0.3525 413 8.2 0.0698
4–10 4035 6.7 1961 7.7 1784 5.5
10–20 1383 8.8 756 9.7 539 6.7
> 20 510 8.4 289 7.3 195 9.2
Lymph node metastasis
N0 3905 7.4 0.2688 1973 7.7 0.1854 1690 6.9 0.8311
N+ 400 9.0 191 10.5 186 6.5
Surgical margin
negative 5390 7.2 0.0416 2694 8.0 0.3797 2300 5.9 0.0581
positive 1366 8.9 664 9.0 620 8.1